Skip to main content

Table 5 Effects of tofogliflozin on markers of renal function, inflammation, and cardio-vascular function

From: Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study

 

Tofogliflozin group

Conventional group

P value

eGFR (mL/min/1.73 m2)

80.7 ± 20.8 (n = 168)

81.9 ± 24.0 (n = 169)

0.64

 Week 26 (change from baseline)

− 2.9 ± 9.1 (n = 161)§

− 2.8 ± 9.4 (n = 162)§

0.89

 Week 52 (change from baseline)

− 2.8 ± 9.5 (n = 159)§

− 2.3 ± 9.6 (n = 161)#

0.67

 Week 78 (change from baseline)

− 3.2 ± 9.9 (n = 154)§

− 3.7 ± 10.4 (n = 157)§

0.65

 Week 104 (change from baseline)

− 3.1 ± 12.1 (n = 155)#

− 3.8 ± 10.5 (n = 153)§

0.59

UAE at baseline (mg/g/cre)

13.0 [6.3, 37.0] (n = 158)

17.4 [5.8, 67.7] (n = 157)

0.24

 Week 26 (change from baseline)

− 0.3 [− 8.9, 6.7] (n = 139)

− 0.4 [− 9.5, 4.5] (n = 134)

0.83

 Week 52 (change from baseline)

− 1.7 [− 8.1, 3.9] (n = 146)*

0.1 [− 5.7, 9.6] (n = 146)

0.038

 Week 78 (change from baseline)

− 0.8 [− 8.3, 8.0] (n = 131)

1.1 [− 6.4, 13.9] (n = 130)

0.06

 Week 104 (change from baseline)

− 1.4 [− 9.9, 5.4] (n = 144)

1.8 [− 3.9, 20.1] (n = 140)*

0.006

hsCRP at baseline (ng/ml)

582.5 [287.5, 1430.0] (n = 168)

619.5 [295.0, 1450.0] (n = 170)

0.70

 Week 52 (change from baseline)

− 24.5 [− 298.0, 190.0] (n = 154)

0.0 [− 260.0, 311.0] (n = 159)

0.41

 Week 104 (change from baseline)

− 45.0 [− 412.5, 172.5] (n = 152)

18.5 [− 300.5, 305.0] (n = 152)

0.21

Adiponectin at baseline (μg/ml)

7.50 [5.30, 10.30] (n = 168)

7.35 [5.40, 10.30] (n = 170)

0.88

 Week 52 (change from baseline)

0.65 [0.10, 1.30] (n = 154)§

0.40 [− 0.30, 1.10] (n = 159)§

0.019

 Week 104 (change from baseline)

0.70 [− 0.10, 1.80] (n = 152)§

0.25 [− 0.30, 1.00] (n = 152)#

0.003

NT-proBNP at baseline (pg/ml)

34.0 [17.0, 68.0] (n = 168)

31.5 [17.0, 59.0] (n = 170)

0.96

 Week 52 (change from baseline)

− 1.0 [− 14.0, 11.0] (n = 154)

− 2.0 [− 13.0, 9.0] (n = 159)

0.94

 Week 104 (change from baseline)

1.0 [− 12.0, 17.0] (n = 152)

2.0 [− 8.5, 17.0] (n = 152)*

0.50

  1. Data are presented as mean ± SD or median (the 25th and 75th percentiles) values. Differences in parameters between groups at baseline were analyzed using Student’s t-test or Wilcoxon rank-sum test. Differences in parameters from baseline to week 52 and 104 within each group were analyzed between groups using a one-sample t-test or Wilcoxon signed-rank test. Differences in parameter changes from baseline to week 52 and 104 were analyzed using Student’s t-test or Wilcoxon rank-sum test. *P < 0.05, #P < 0.01, §P < 0.001
  2. eGFR, estimated glomerular filtration rate; UAE, urinary albumin excretion; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro–brain natriuretic peptide; baPWV, brachial-ankle pulse wave velocity; ABI, ankle brachial blood pressure index
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840